Daily Intelligence for Biotech Investors

The deal tapeserious biotech investors actually read

Top news, M&A, BD&L, IPOs, and VC financings — distilled to a 5-minute read every market morning. No hype. No filler. Just the signal.

Trusted by 2,000+ biotech execs, VCs, BD leads, public market investors - free

Latest Editions

Daily

Nov 6

Friday: RevMed books $198M in five weeks

Plus: AstraZeneca's reported $10B swing at Rhythm, and nine Zolgensma tumor reports.

Nov 5

Thursday: Boehringer's $7B China bet

Plus: CVS splits in two and AbbVie revives a pill Nxera shelved.

Nov 4

Wednesday: Servier's $1.55B bet hits a wall

Plus: Novo's third guidance raise on the Wegovy pill and Pfizer's ex-Covid growth.

Nov 3

Tuesday: uniQure gets its May 1 date as Inovio finally gets a yes

Plus Inovio's first DNA medicine, Lonza's five-site CDMO buy and Karyopharm's Chapter 11.

Nov 2

Monday: AstraZeneca trims to find $1.5B

Regeneron prints a 36% quarter, and an Alzheimer's oligomer bet comes up empty.

2,000+

Subscribers

5×

Issues per week

16+

Research reports

~$207.8B

M&A tracked YTD

READ BY PROFESSIONALS AT

Research Hub

Live trackers & research

View all →

Live Trackers

Live Tracker

Biotech & Pharma M&A Tracker 2026

Every control transaction in 2026 — target, acquirer, deal value, premium-to-unaffected, and investor-grade rationale. 76 deals. ~$207.8B tracked.

Last updated 6 November 2026

Live Tracker

Biotech BD&L Tracker 2026

Licensing and partnering deals — upfronts, milestones, royalties, territory rights, and a one-line why it matters. 184 deals. Up to US$18.5B largest package.

Last updated 6 November 2026

Live Tracker

Biotech IPO Tracker 2026

Every biotech IPO this year — pricing date, proceeds, valuation at pricing, and aftermarket performance. 30 deals. ~$9.1B tracked.

Last updated 6 November 2026

Live Tracker

Biotech Funding Rounds 2026

Funding rounds and selected biotech financings — company, amount, stage, investors and source links. 223 deals. US$2.1B largest round.

Last updated 6 November 2026

Research

Report

Most Active Biotech Investors 2026

Ranked league table of the most active biotech and biopharma investors in 2026 by qualifying deal participation.

Reference

Top 50 Biotech Investors in Europe 2026

Every leading biotech investor in the UK and EU — headquarters, investor type, stage focus and why they matter. 50 investors mapped across 11 countries.

Reference

Biotech Conference Calendar 2026

Major biotech and biopharma conferences in 2026 across the US, UK, and EU, including investor events, scientific catalysts, and partnering meetings.

Report

Top 10 BioPharma M&A Deals of 2025

Ranked list of the 10 biggest biopharma and biotech acquisitions announced in 2025, with stage, therapeutic area, and investor-grade read-through.

Report

Biotech M&A H1 2026 Report

49 deals, ~$149B in value. Q2 nearly doubled Q1. Five $10B+ takeouts, all in Q2. Lilly signed 11 deals.

Report

Biotech M&A Q1 2026 Report

16 deals, $44B in value, and what the deal tape signals about where strategic buyers are paying up.

Report

2024 Biopharma M&A: Every $1B+ Deal

The complete list of 2024 biopharma acquisitions worth $1B or more — public and private targets.

Reference

Biotech Funding Terms Glossary

Plain-English definitions of the deal terms that appear in press releases, term sheets, IPOs, and M&A announcements.

About BioBucks

BioBucks is a daily newsletter for biotech and biopharma investors — covering M&A, BD&L deals, IPOs, venture rounds, and catalyst-driven market moves, with the framing that institutional dealmakers actually care about.

Every edition is written to be read in under 5 minutes, with the why it matters front and centre. No press release regurgitation. No noise.

Alongside the daily tape, the Research Hub provides live trackers and standalone reports that serve as reference tools for the community.

Who reads BioBucks

VC / GrowthBiotech venture investors tracking the deal environment

BD&LBusiness development professionals monitoring partnerships

Public MarketsBuyside analysts and portfolio managers

FoundersBiotech CEOs watching comps and M&A premiums